AI-POWR Trademark

Downloadable and prerecorded computer software using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted pharmaceutical treatments and therapies, and to select patients that will respond to pharmaceutical treatments and therapies; downloadable and prerecorded computer software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations; downloadable and prerecorded computer software using artificial intelligence for analyzing non-clinical data, preclinical data, and clinical data, for analyzing the results of clinical trials or studies, for evaluating clinical outcomes and treatment responses, for patient identification and a priori responder selection, for individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; downloadable and prerecorded computer software using artificial intelligence for selection and identification of drugs, drug targets, and drug combination selection and evaluation, for biomarker selection, for genetic data analyses, for omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and for accessing and processing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and for disease and drug analysis in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; all of the aforesaid excluding computer software for application and database integration

Design, development, computer programming, testing, maintenance, customization, and operation of computer software in clinical trials or studies; designing clinical trials or studies; clinical research in the field of improving the efficacy of clinical trials and studies and de-risking clinical trial or study designs, clinical trials simulations, and clinical endpoint selection; clinical research, namely, analyzing non-clinical data, preclinical data, and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; clinical research in the field of patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination, selection, and identification, drug, drug target, and drug combination selection and evaluation, biomarker selection, genetic analyses, omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, designing clinical trials or studies, de-risking clinical trial or study designs, conducting clinical trials simulations, clinical endpoint selection, analyzing preclinical data and clinical data, analyzing results of clinical trials or studies, and evaluating clinical outcomes and treatment responses; consulting, consultancy, and consulting services related to clinical trials or studies, namely, conducting patient identification and a priori responder selection, individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for precision medicine, namely, to decode diseases, develop targeted pharmaceutical treatments and therapies, and to select patients that will respond to pharmaceutical treatments and therapies; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for bioinformatics, simulations in clinical trials or studies, the designing of clinical trials or studies, and the de-risking of clinical trial or study designs and clinical trials simulations; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for analyzing non-clinical data, preclinical data, and clinical data, for analyzing the results of clinical trials or studies, for evaluating clinical outcomes and treatment responses, for patient identification and a priori responder selection, for individualizing treatments, predicting clinical outcomes and treatment responses, and disease diagnoses and treatment determination; platform as a service (PaaS) featuring computer platforms and software using artificial intelligence for selection and identification of drugs, drug targets, and drug combination selection and evaluation, for biomarker selection, for genetic data analyses, for omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics analyses, and for accessing and processing omics, multiomics, genomics, transcriptomics, proteomics, lipidomics, and metabolomics data, and for disease and drug analysis in the medical field, biomedical field, healthcare field, pharmaceutical field, and biotechnological field; all of the aforesaid excluding computer software and services for application and database integration